Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
- Celgene Launches Japan PI for Pleiotropic Pathway Modifier
September 29, 2015
- Chugai to Create New Post to Gear Up for HTA Introduction
September 28, 2015
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- Achieving New Share Target for Generics Will Be “Quite Difficult”: Hengrui Japan President
September 25, 2015
- Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
- Novartis Files Afinitor for GI and Lung Neuroendocrine Tumors in Japan
September 24, 2015
- Amgen Gets Rights to MTPC’s Dyslipidemia Drug after Dezima Acquisition
September 18, 2015
- Chugai Seeks Cervical Cancer Indication for Avastin
September 18, 2015
- Opdivo Gets Breakthrough Therapy Designation for RCC
September 18, 2015
- 1 in 4 Elderly Japanese on 5 or More Prescribed Meds: Pharmacy Survey
September 17, 2015
- Eli Lilly’s Once-Weekly GLP-1 Hits Japan Market
September 17, 2015
- RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…